Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PARL | Q9H300 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503175 | 0.81 | ALDH1A1 (0.43) | MAPTHSD17B10ALDH1A1RAB9ANPC1 | |
| SCHEMBL11569738 | 0.78 | MEN1 (0.41) | MAPTHSD17B10ALDH1A1RAB9ANPC1 | |
| SCHEMBL7341984 | 0.78 | CRBN (0.39) | MAPTHSD17B10ALDH1A1RAB9ANPC1 | |
| SCHEMBL11090245 | 0.78 | CRBN (0.39) | MAPTALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL28539505 | 0.78 | ALDH1A1 (0.38) | MAPTHSD17B10ALDH1A1RAB9ANPC1 | |
| SCHEMBL28493477 | 0.78 | FAAH (0.38) | MAPTHSD17B10ALDH1A1MGLL | |
| SCHEMBL7337733 | 0.78 | CRBN (0.39) | MAPTHSD17B10ALDH1A1RAB9AMEN1 | |
| SCHEMBL1165632 | 0.78 | MAPT (0.44) | MAPTHSD17B10ALDH1A1PARLRAB9A | |
| SCHEMBL1041075 | 0.78 | MAPT (0.41) | MAPTHSD17B10ALDH1A1PARLRAB9A | |
| SCHEMBL31599173 | 0.77 | ALDH1A1 (0.39) | MAPTHSD17B10ALDH1A1MGLLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492220-B2 | Method for the preparation of oligonucleotides | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2025-12-09 | — | — | US | claimed |
| CN-118598736-A | Synthesis method of alpha, beta-unsaturated carbonyl compound | 中山大学 | 2024-09-06 | — | — | CN | claimed |
| CN-118515585-A | Synthesis method of alkenyl cyanide compound | 中山大学 | 2024-08-20 | — | — | CN | claimed |
| US-20230192751-A1 | METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2023-06-22 | — | — | US | claimed |
| US-12492220-B2 | Method for the preparation of oligonucleotides | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2025-12-09 | — | — | US | disclosed |
| CN-118598736-A | Synthesis method of alpha, beta-unsaturated carbonyl compound | 中山大学 | 2024-09-06 | — | — | CN | disclosed |
| CN-118515585-A | Synthesis method of alkenyl cyanide compound | 中山大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-106922129-B | Methods of conjugating polypeptides | 免疫医疗有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117165966-A | Method for constructing N-thioether substituted sulfoxide imine derivative through electrochemical promotion | 桂林理工大学 | 2023-12-05 | — | — | CN | disclosed |
| US-20230192751-A1 | METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2023-06-22 | — | — | US | disclosed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| CN-113683548-B | Preparation method of 3, 4-dithiopyrrole material | 太原理工大学 | 2022-12-27 | — | — | CN | disclosed |
| EP-0052299-A1 | 2-Oxoazetidine derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1982-05-26 | — | — | EP | disclosed |
| US-4283508-A | Fragrant prevulcanization inhibitors | MONSANTO COMPANY (US) | 1981-08-11 | — | — | US | disclosed |
| US-4278686-A | ANTIBIOTICS | BEECHAM GROUP LIMITED (GB) | 1981-07-14 | — | — | US | disclosed |
| EP-0005914-A1 | Chemical process for the preparation of beta-lactamase inhibitors, and so obtained compounds | BEECHAM GROUP PLC (GB) | 1979-12-12 | — | — | EP | disclosed |
| EP-0005348-A1 | Carbapenem derivatives, a process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1979-11-14 | — | — | EP | disclosed |
| EP-0005349-A1 | Alkylcarbapenems, their preparation, use in pharmaceutical compositions and intermediates | BEECHAM GROUP PLC (GB) | 1979-11-14 | — | — | EP | disclosed |
| US-4119780-A | 2(Isopropyldithio)benzimidazole | MONSANTO COMPANY (US) | 1978-10-10 | — | — | US | disclosed |
| US-4006155-A | Method for preparation of phosphorus polysulfides | MONSANTO COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | MAPT 3183/4885HSD17B10 1121/4885ALDH1A1 3610/4885 |
| US-12492220-B2 | Method for the preparation of oligonucleotides | POLN, POLRMT, POLI | MAPT 3637/4885HSD17B10 4366/4885ALDH1A1 4284/4885 |
| US-20230192751-A1 | METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES | POLN, POLRMT, POLI | MAPT 3637/4885HSD17B10 4366/4885ALDH1A1 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.